Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Ovid Therapeutics stock

Learn how to easily invest in Ovid Therapeutics stock.

Ovid Therapeutics Inc is a biotechnology business based in the US. Ovid Therapeutics shares (OVID) are listed on the NASDAQ and all prices are listed in US Dollars. Ovid Therapeutics employs 49 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Ovid Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OVID – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Ovid Therapeutics stock price (NASDAQ: OVID)

Use our graph to track the performance of OVID stocks over time.

Ovid Therapeutics shares at a glance

Information last updated 2022-06-24.
Latest market close$2.15
52-week range$1.65 - $4.42
50-day moving average $2.35
200-day moving average $3.06
Wall St. target price$4.70
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.95

Buy Ovid Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
Financial advice powered by relationships, not commissions.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ovid Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ovid Therapeutics price performance over time

Historical closes compared with the close of $2.15 from 2022-06-30

1 week (2022-06-24) 12.57%
1 month (2022-05-28) N/A
3 months (2022-03-30) -32.18%
6 months (2021-12-28) N/A
1 year (2021-07-01) -45.57%
2 years (2020-07-01) -70.59%
3 years (2019-07-01) 2.31
5 years (2017-06-30) 10.49

Is Ovid Therapeutics stock undervalued or overvalued?

Valuing Ovid Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ovid Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ovid Therapeutics's EBITDA

Ovid Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $124.4 million.

The EBITDA is a measure of a Ovid Therapeutics's overall financial performance and is widely used to measure a its profitability.

Ovid Therapeutics financials

Revenue TTM $1.4 million
Gross profit TTM $208.4 million
Return on assets TTM -20.01%
Return on equity TTM -35.89%
Profit margin 0%
Book value $2.34
Market capitalisation $134.5 million

TTM: trailing 12 months

Ovid Therapeutics share dividends

We're not expecting Ovid Therapeutics to pay a dividend over the next 12 months.

Ovid Therapeutics share price volatility

Over the last 12 months, Ovid Therapeutics's shares have ranged in value from as little as $1.65 up to $4.42. A popular way to gauge a stock's volatility is its "beta".

OVID.US volatility(beta: 1.58)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ovid Therapeutics's is 1.583. This would suggest that Ovid Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ovid Therapeutics overview

Ovid Therapeutics Inc. , a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Frequently asked questions

What percentage of Ovid Therapeutics is owned by insiders or institutions?
Currently 23.371% of Ovid Therapeutics shares are held by insiders and 52.614% by institutions.
How many people work for Ovid Therapeutics?
Latest data suggests 49 work at Ovid Therapeutics.
When does the fiscal year end for Ovid Therapeutics?
Ovid Therapeutics's fiscal year ends in December.
Where is Ovid Therapeutics based?
Ovid Therapeutics's address is: 1460 Broadway, New York, NY, United States, 10036
What is Ovid Therapeutics's ISIN number?
Ovid Therapeutics's international securities identification number is: US6904691010
What is Ovid Therapeutics's CUSIP number?
Ovid Therapeutics's Committee on Uniform Securities Identification Procedures number is: 690469101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site